Compare TOP & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOP | SNTI |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 31.5M |
| IPO Year | 2021 | 2021 |
| Metric | TOP | SNTI |
|---|---|---|
| Price | $2.23 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 434.5K | 292.5K |
| Earning Date | 01-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.25 | 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,723,765.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.89 | N/A |
| 52 Week Low | $0.61 | $0.42 |
| 52 Week High | $3.33 | $2.88 |
| Indicator | TOP | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 21.66 |
| Support Level | $0.89 | N/A |
| Resistance Level | $2.88 | $1.02 |
| Average True Range (ATR) | 0.33 | 0.09 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 40.16 | 0.97 |
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).